Connect with us

Business

Invest Ghana Summit: NVI Pitches Vaccine Manufacturing Opportunities to Investors

Published

on

When the CEO of the National Vaccine Institute (NVI), Dr Sodzi Sodzi-Tettey, took the stage at the maiden Invest Ghana Summit 2026, he came with a simple proposition: Ghana spends roughly $50 million every year buying vaccines for mothers and children from abroad. By 2030, he argued, that money should be building an industry at home.

Speaking at a side meeting of the summit, held November 16 to 17 at the Kempinski Gold Coast City Hotel in Accra under the theme “Investing in Ghana’s New Economy: Building a Productive Economy that Creates Value and Competes Globally,” the NVI boss laid out three concrete opportunities for investors and the government interventions already underway to de-risk them.

The Scale of the Prize

Ghana imports about 70% of its medicines and pays up to $50 million annually for vaccines alone.

“The question is whether we are going to continue to mobilize 50 million dollars which we can use it to invest in other people’s economy under the guise of buying the vaccines, or we are going to invest in the economy,” Dr Sodzi-Tettey told the room. “The President has decided that we are going to invest it in the economy.”

That decision, he said, is why the NVI was established to coordinate the ecosystem and partner with manufacturers to make Ghana a vaccine-manufacturing country.

Opportunity One: The NVI Itself

The government has allocated about $50 million to the NVI, and the agency is inviting collaboration in four areas:

– A National Vaccine Database. “At this point we do not have any uniform end-to-end data set that shows you what is happening in the ecosystem,” the CEO said. The NVI plans to build one.

– A central GMP plant. University researchers are developing vaccine candidates, but “the path to commercialization is not clear.” The proposed facility would carry products from basic research through clinical trials to manufacturers, including a pipeline of products one university partner needs manufactured to Class C and E standards.

– Simulation Center. An ecosystem assessment found manufacturing skills to be “the weakest” link. The center would offer hands-on training beyond the theoretical instruction students receive in schools.

– A sensitization campaign launching next year, driven by survey findings that only 14% of Ghanaians know about local manufacturing.

Opportunity Two: Two Manufacturers, Ready for Partnership

The CEO named two vaccine manufacturers already working in partnership with the NVI as specific investment opportunities: Atlantic Life Sciences and DEK Vaccines Limited. Both companies together require investment to the tune of $65 million for the first phase of work and remain open to equity investments.

Investors were also told the partnerships form part of the public-private collaboration agenda. 

Opportunity Three: The Ghana Pharmaceutical Hub

Described as a separate project from the vaccine institute’s work, the Ghana Pharmaceutical Hub comes with significant government backing. As announced in the budget, the government is allocating up to $1 billion to the initiative.

“This is the golden era of the pharmaceutical industry in the country,” the CEO said. “There’s just so much happening in the space.”

Other ecosystem enablers being spearheaded by the Ghana goovernment and NVI to make investments attractive include the following:

1. Newly approved Ghana Pharmaceutical Manufacturing Policy

2. Ghana signing onto the African Pooled Procurement Mechanism (APPM) to open up the 1.4 billion African market to Ghanaian manufacturers; and

3. Commitment by the government to purchase locally manufactured medicines

The Pitch

The pitch was less a request for capital than a map of where public money is already moving, $50 million to the NVI, up to $1 billion to the pharma hub, and where private partners fit in. Each opportunity the CEO outlined, he stressed, “are opportunities for collaboration between NVI and will-be investors.”

Dr Sodzi-Tettey stated that the economic case for vaccine research and immunization is among the strongest in public health, the basis for NVI’s R&D co-funding platforms.

“A $16 return per $1 invested in immunization in 94 low- and middle-income countries, 2011–2020 (cost-of-illness approach). $44 per $1 when broader economic and social benefits are included and $52 per $1 under the value-of-statistical-life approach in updated Decade of Vaccine Economics modelling. The implication for investors: co-funded research through NVI is not philanthropy, it is the highest-leverage entry point into the ecosystem,” he stressed.

The address came a few days before the government showcased its broader investment agenda, and it dovetailed with remarks elsewhere in the on Wednesday, Nov. 18, 2026, by Health Minister Kwabena Mintah Akandoh, who said Ghana’s first locally bottled vaccines are expected on the market in 2027, with support from Indonesian partners.

For investors, the message was clear: Ghana is converting a recurring import bill into a domestic industry, and it is looking for partners to help build the database, the plant, the workforce, and the market along the way.

The Invest Ghana Summit 2026 was hosted by President John Dramani Mahama and convened by the Ghana Investment Promotion Authority alongside key ministries and agencies, followed by the Ghana Club 100 on November 18.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Ghanaian Pharmaceutical Manufacturers Begin Breaking Into African Markets Thanks to Africa CDC’s Pooled System

Published

on

Ghanaian pharmaceutical manufacturers are beginning to secure supply opportunities in other African countries as the continent advances efforts to create a more coordinated market for medicines produced within Africa.

The development has been made possible through the African Pooled Procurement Mechanism (APPM), an initiative established by the Africa Centres for Disease Control and Prevention (Africa CDC).

The APPM is expected to expand commercial opportunities for local manufacturers while helping participating countries improve access to quality-assured health products.

At a regional meeting jointly organized by the National Vaccine Institute (NVI) and the Africa CDC, Dr Sodzi Sodzi-Tettey, Chief Executive Officer of NVI, disclosed that Ghanaian companies had won new tenders to supply Uganda, South Sudan, the Democratic Republic of the Congo and Ethiopia.

His announcement was part of his opening remarks during the two-day regional meeting on the APPM that started on November 10, 2026. At the meeting, government officials, manufacturers, procurement authorities and regulators discussed how to increase African participation in the continental procurement system.

The move is significant for Ghana’s pharmaceutical industry, which is seeking to expand beyond the domestic market and benefit from procurement opportunities across a continent with a population of approximately 1.4 billion.

For local manufacturers, access to larger markets could provide the demand needed to justify investment in additional production capacity, improve economies of scale and strengthen the competitiveness of Ghana-made medicines.

It also supports the government’s broader ambition to increase local production from a reported 30 per cent of medicines used in Ghana to 70 per cent within five years.

From a continental concept to actual supply opportunities

The APPM is designed to aggregate demand from participating African countries, strengthen their collective purchasing power and connect national procurement requirements with qualified African manufacturers.

By coordinating demand and procurement, the mechanism aims to create a more predictable market for producers while improving access to affordable, quality-assured medicines and other health products.

Sodzi-Tettey said the initiative had made significant progress since he assumed office at the NVI a little over a year ago.

“When I came into office a little over a year ago, the APPM was but a concept. On paper. In this short time, thanks to the dynamic leadership of Dr. Mariatou Tala, the APPM is today launching tenders, pre qualifying suppliers and on boarding manufacturers,” he said.

He praised Dr Mariatou Tala Jallow, Director of the APPM at Africa CDC, for helping move the initiative towards operational implementation.

Tala Jallow said the mechanism was transitioning from its operational phase towards consolidation and expansion, with a focus on connecting African manufacturers to the purchasing needs of participating countries.

“Through this engagement, Africa CDC is supporting Member States to translate their participation into tangible procurement opportunities and stronger continental manufacturing capacity,” she said.

The reported tender successes involving Ghanaian companies are an important development because they demonstrate how regional procurement arrangements could create opportunities beyond individual national markets.

However, the disclosure did not identify the companies involved, the specific medicines supplied, the contract values or the volumes covered by the tenders.

Those details will be important in assessing the commercial scale and longer-term impact of the reported awards.

Ghana’s manufacturers face a much larger continental opportunity

Despite the reported progress, Ghanaian manufacturers remain underrepresented in the APPM registration process.

Sodzi-Tettey disclosed that out of 108 companies registered under the mechanism, only 19 were from West Africa, representing 17.6 per cent. Ghana accounted for just three companies, equivalent to 2.8 per cent of the total.

The figures highlight a significant opportunity for Ghanaian pharmaceutical companies to become more involved in a procurement system intended to connect African suppliers to a much larger market.

The NVI chief executive called for manufacturers and other industry stakeholders to take advantage of the changing pharmaceutical landscape rather than remain focused on historical challenges.

His message was directed particularly at Ghanaian and West African manufacturers, whose participation will be important if the region is to secure a stronger position in continental pharmaceutical trade.

Ghana signed a memorandum of understanding with Africa CDC to participate in the APPM on August 21, 2026, providing a framework for the country’s engagement with the mechanism.

Participation, however, does not automatically qualify every manufacturer for contracts. Suppliers must still meet relevant product approval, regulatory, quality assurance and competitive tendering requirements.

Why access to regional markets matters

For pharmaceutical manufacturers, the ability to sell beyond their domestic market can be a major factor in determining whether an investment is commercially viable.

Production facilities, specialized equipment, skilled personnel, quality assurance systems and regulatory compliance all involve substantial costs.

When a manufacturer serves only a relatively small domestic market, it may struggle to achieve the production volumes needed to spread those costs and remain competitive.

Access to several national markets could help address this problem.

The APPM’s demand aggregation approach is intended to make purchasing opportunities more visible and predictable, potentially allowing manufacturers to plan production around larger regional requirements.

That could also help address a financing problem highlighted by Sodzi-Tettey: banks are often reluctant to lend to manufacturers without evidence of dependable future revenue.

He said some companies had spent almost two years pursuing development financing before proposed deals collapsed because lenders lacked confidence in their ability to repay loans in the absence of robust multi-year purchasing agreements.

A more predictable procurement environment could improve manufacturers’ ability to secure financing, although the success of that approach will depend on credible contracts, funded purchasing commitments and reliable payments by buyers.

Ghana is building domestic capacity to support regional expansion

The reported regional tender successes come as Ghana advances plans to strengthen its own pharmaceutical manufacturing ecosystem.

The government has launched the Ghana Pharmaceutical Manufacturing Policy and is developing a proposed Ghana Pharmaceutical Hub as part of its wider industrial transformation agenda.

The hub is intended to connect manufacturers to production infrastructure, shared laboratories, utilities, logistics, investment and training.

Its first proposed development phase is in Kwanyarko in the Eastern Region, with plans for five initial contract manufacturing facilities, ten modular factory shells, shared laboratories, utilities, warehousing and cold-chain infrastructure.

A proposed second phase in the Central Region would focus on active pharmaceutical ingredients, plant-based medicines, research, raw materials and packaging materials.

The presidential staffer for Health and Pharmaceuticals, who also coordinates the Ghana Pharmaceutical Hub, said the initiative was designed around a demand-led model connecting verified domestic and regional demand to investment, local manufacturing, procurement and market access.

The government has also outlined safeguards intended to support fair participation by both manufacturers and existing pharmaceutical importers, including transparent supplier selection, clear commercial arrangements and protection of intellectual property.

The objective is to encourage existing businesses to participate in local production rather than exclude companies whose experience, brands, technical relationships and distribution networks could support the industry’s expansion.

Quality and competitiveness will determine long-term success

While the APPM could open new markets, Ghanaian manufacturers will need to demonstrate that they can supply products consistently, competitively and in accordance with the quality standards required by participating countries.

Regulatory approval, technical specifications, product quality, manufacturing reliability and the ability to fulfil contracts will remain essential.

The Accra meeting therefore placed considerable emphasis on supplier readiness, demand forecasting, the APPM Supply Catalogue, quality assurance and the procurement procedures applicable to participating countries.

For Ghana, the challenge now is to convert early commercial opportunities into sustained regional market participation.

The reported tenders involving Uganda, South Sudan, the DRC and Ethiopia offer an encouraging indication of what may be possible, but the longer-term measure of success will be whether Ghanaian companies can secure repeat business, expand production and build a durable presence in African pharmaceutical supply chains.

If that happens, the benefits could extend well beyond individual manufacturers, supporting investment, skilled employment, industrial development and greater access to medicines across the continent.

Ghana’s emerging position in the APPM therefore represents more than an export opportunity. It is part of a wider African effort to build a pharmaceutical industry capable of serving the continent’s health needs with products manufactured within its own borders.

Continue Reading

Business

Ghana Seeks Investors to Revive National Airline After Advanced Talks with Boeing

Published

on

Ghana is in advanced negotiations with US aerospace giant Boeing over plans to establish a new national airline, with the government working to finalise arrangements and attract investors to the proposed carrier, Ghana’s Ambassador to the United States, Victor Smith, has disclosed.

Speaking in an interview with JoyNews, Mr Smith said discussions with Boeing were nearing completion, raising the prospect of Ghana restoring a national flag carrier more than two decades after the collapse of Ghana Airways.

“We are in talks with Boeing. The deal is nearing completion. We are working to ensure that Ghana has a national airline that we can all be proud of,” he said.

The Ambassador did not disclose the specific terms under discussion, the proposed ownership structure or the financial commitments involved. He also did not provide a timeline for concluding the negotiations or launching the airline.

Government seeking investors for national carrier

Mr Smith said attracting investors was an important part of the government’s effort, suggesting that the proposed airline could offer commercial opportunities for those willing to participate.

“We are looking for investors. They may invest in this effort. They may get something out of it,” he said.

However, he emphasised the symbolic and national significance of restoring a Ghanaian carrier, describing it as a potential legacy of President John Dramani Mahama’s administration.

“What is important for me is the legacy that the President will leave when he’s leaving office—that we will have a national flag back in the air. That is important for me,” he added.

His remarks indicate that the government is pursuing both an investment-led approach and a broader national ambition to restore Ghana’s presence in international aviation.

Ambassador points to public enthusiasm

Mr Smith also argued that Ghanaians would welcome the return of an airline carrying the country’s flag, suggesting that national identity and passenger confidence could contribute to public support for the project.

“Ghanaians are more excited flying their own flag than flying British Airways or Delta or United and being charged huge amounts for tickets,” he said.

“They think that we would feel more comfortable and fly in our own flag.”

His comments reflect the government’s expectation that a national carrier could appeal to travellers seeking a Ghanaian airline option. However, the proposed airline’s routes, fares, service model and competitive position in the international aviation market have not yet been outlined.

Ghana’s long search for a national airline

Ghana has been without a national airline since Ghana Airways collapsed in 2004. Ghana International Airlines, established as a subsequent attempt to restore the country’s flag-carrier status, also ceased operations in 2010.

Successive governments have explored ways to re-establish a national carrier, including potential partnerships with international aviation companies, but those efforts have yet to produce a lasting replacement.

The latest initiative represents another attempt to restore Ghana’s position in commercial aviation through a partnership involving an international industry player.

Boeing is one of the world’s major aircraft manufacturers, but the extent of its proposed involvement in Ghana’s project remains unclear. The Ambassador’s comments do not establish whether the discussions concern aircraft purchases, leasing arrangements, technical support or a broader partnership.

Key questions remain over ownership and operations

Although the government says negotiations are nearing completion, several important details about the proposed airline remain outstanding.

These include how the carrier will be financed, whether it will be wholly state-owned or involve private investors, the number and type of aircraft it will operate, its initial destinations and the date it is expected to begin commercial services.

Its long-term viability will also depend on its ability to compete in an established aviation market, maintain operational efficiency and secure sufficient passenger demand.

For now, Mr Smith’s disclosure provides an indication of progress in the government’s discussions with Boeing, but a final agreement and a clearly defined operational plan will be necessary before Ghana’s proposed national carrier can move from ambition to reality.

Continue Reading

Business

$2bn Without Borrowing: How Ghana Is Funding the Accra-Kumasi Expressway

Published

on

In a bold departure from Ghana’s traditional reliance on external debt, the government has announced that the entire $2 billion needed to finance the Accra-Kumasi Expressway has been secured from domestic sources, with no borrowing involved.

President John Dramani Mahama has confirmed that $2 billion, sourced from taxpayers’ money, has been deposited in a special account at the Bank of Ghana.

“And let me also announce that this is our own money. We have not gone to borrow money from anywhere. This money is the taxpayers’ money,” the President stated at the handover ceremony of the cleared right-of-way on September 14, 2026.

No Borrowing, No Debt Burden

Finance Minister Dr. Cassiel Ato Forson has reinforced this commitment, assuring the nation that “we will not borrow a pesewa for this construction”.

He stated that the full amount required will be ready by December 31, 2026, and reiterated that the government plans to mobilise the required funds entirely from domestic sources, allowing the project to proceed without adding to Ghana’s debt burden.

Timely Payments to Contractors

The funds are lodged in a dedicated account to facilitate timely payments to the contractor throughout the duration of the project.

President Mahama assured that all payment certificates submitted by the contractor would be honoured promptly to prevent delays and ensure the project progresses as scheduled. The project is being managed by a special purpose vehicle, Accra Kumasi Expressway Limited, registered for this purpose.

The GAF Factor in Cost Savings

The government’s domestic financing strategy has been bolstered by significant cost savings from the involvement of the Ghana Armed Forces (GAF) Engineers.

The GAF cleared 175.6 kilometres of the right-of-way in just 19 weeks—beating a 20-week target—at an estimated cost of GH₵10.9 billion, compared with commercial contractor baselines of GH₵15–18 billion. This yielded billions of cedis in net savings.

The $2 billion domestic financing model represents a significant shift in Ghana’s infrastructure funding approach. If successfully executed, it could provide a template for future mega-projects, demonstrating that national development need not come at the cost of mounting external debt.

Continue Reading

Trending